Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2)

NCT05624827 is registered in ClinicalTrials.gov with University Medical Centre Maribor as lead sponsor.

NCT NCT05624827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05624827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2)
Lead sponsor
University Medical Centre Maribor
Phase
Not applicable
Overall status
Unknown status
Start date
September 1, 2021
Completion date
May 1, 2024
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia grade 2, dna methylation